Trade IFRX

Inflarx NV

00:00:00

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company’s C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Name	Sell	1D Chg
SMTC Semtech Corp	41.72	6.357%
FDX Fedex	265.28	0.501%
NIO NIO Limited	6.270	1.294%
DOYU DouYu International Holdings Ltd - ADR	9.558	0.899%
DVMT Dell Technologies Inc	124.57	0.817%
TSLA Tesla Motors	240.91	-0.339%

How it works:

Use our margin calculator to determine the funds required to open and maintain positions.

Select your account base currency, an asset pair, the size of your position in lots, and your level of leverage.

The calculation is carried out as follows:
Required Margin = Trade Size / Leverage * Account Currency Exchange Rate

Profit/Loss Calculator

Account Base Currency

Instrument

Volume in Lots (Contract Size 100,000)

Price

Long Buy Short Sell

Set Stop Loss Amount :

Set Profit Amount :

Calculation Results

PIP Value:

Stop loss in PIPs

Stop loss at :

Take profit in PIPs

Take profit at :

How it works:

Use our profit and loss calculator to determine where to place your take profit and stop loss.

Select your account base currency, an asset pair, the size of your position in lots, choose between a long buy and a short sell, and input a stop loss and take profit value.

The calculation is carried out as follows:
SL / TP Levels = SL, TP Amount / Pip Value Formula * Exchange Rate